Wouter Joustra

General Partner

2020 - Current

FEAC Board Director (NASDAQ now: ENGN)

2021 - 2023

De-SPAC with Engene, NASDAQ: ENGN

Partner

2019 - 2020

Board Member

2024

Board Member

2024

Board Member (NASDAQ: NAMS)

2024

Board Member (Observer) (NASDAQ: NAMS)

2021 - 2024

Board Member (NASDAQ: ENGN)

2024

Board Member

2023

Board Member & Founding Investor - Sold to GSK for up to $1.4bn

2023 - 2024

Board Member (NASDAQ: VECT) - Sold to Ironwood for $1.2bn

2022 - 2023

Board Member - Sold to Novartis for up to $1.5bn

2021 - 2022

Executive Boardmember Life Sciences Franchise

2017 - 2019

Senior Life Sciences Trader

2016 - 2019

• Actively running Kempen’s Life Sciences portfolio • Specialized in European Life Sciences & Biotech • Involved in deal structuring, equity capital market transactions, crossing large blocks of company shares (for example placed >€150mln notional in Argenx at market levels in 2019), deal structuring through warrants/derivatives • Developed an extensive network with both corporates, and specialized investors